| Chemotherapy, n (%) |
104 (100) |
| 4 cycles
|
94 (90.1) |
| < 4 cycles
|
10 (9.6) |
|
Cumulative ifosfamide dose, mean (g/m2) (stdev)
|
19.4 (2.5) |
|
Cumulative doxorubicin dose, mean (g/m2) (stdev)
|
290.2 (37.2) |
| Dose reduction, n (%) |
12 (11.7) |
| Radiotherapy, n (%) |
89 (86.4) |
| Sandwich, n (%) |
79 (76.0) |
| Before chemotherapy, n (%) |
10 (9.6) |
| Total radiotherapy dose, mean (Gy) (stdev) |
61.7 (4.7) |
| Adherence to protocol, n (%) |
|
| Yes
|
84 (80.8) |
| No
|
19 (18.3) |
| Recurrent disease during treatment
|
3 (2.9) |
| Infection/complications
|
10 (9.6) |
| Mesh graft too fresh for radiotherapy
|
1 (1.0) |
| External previous treatment
|
2 (1.9) |
| Neoadjuvant treatment
|
2 (1.9) |
| Patient‘s wish
|
1 (1.0) |
| Time from surgery to start of cycle 1 of chemotherapy |
|
| Median (range), days
|
31 (8–148) |
| Time from surgery to last chemotherapy (cycle 4) |
|
| Median (range), days
|
177 (80–271) |
| Median follow-up (range), month |
39 (5–194) |
